MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Equity Offerings

Macrogenics (MGNX) Prices 5.5M Share Common Offering at $20/ShFebruary 13, 2019 5:53 AM MacroGenics Announces Proposed Public Offering of Common StockFebruary 12, 2019 4:01 PM